Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
TEVA PHARMA Dec-13 |
DISHMAN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 3,117 | - | |
Low | Rs | 129 | 2,708 | - | |
Sales per share (Unadj.) | Rs | 197.8 | 1,788.7 | - | |
Earnings per share (Unadj.) | Rs | 21.2 | 111.7 | - | |
Cash flow per share (Unadj.) | Rs | 34.7 | 256.3 | - | |
Dividends per share (Unadj.) | Rs | 2.00 | 97.82 | - | |
Dividend yield (eoy) | % | 0.8 | 3.4 | 23.7% | |
Book value per share (Unadj.) | Rs | 179.9 | 1,986.9 | - | |
Shares outstanding (eoy) | m | 80.69 | 848.00 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 1.6 | 78.1% | |
Avg P/E ratio | x | 11.9 | 26.1 | 45.5% | |
P/CF ratio (eoy) | x | 7.2 | 11.4 | 63.8% | |
Price / Book Value ratio | x | 1.4 | 1.5 | 95.4% | |
Dividend payout | % | 9.4 | 87.5 | 10.8% | |
Avg Mkt Cap | Rs m | 20,306 | 2,469,486 | 0.8% | |
No. of employees | `000 | 0.8 | 44.9 | 1.8% | |
Total wages/salary | Rs m | 5,355 | 0 | - | |
Avg. sales/employee | Rs Th | 19,252.7 | 33,748.9 | 57.0% | |
Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
Avg. net profit/employee | Rs Th | 2,064.1 | 2,108.3 | 97.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 1,516,846 | 1.1% | |
Other income | Rs m | 265 | 0 | - | |
Total revenues | Rs m | 16,226 | 1,516,846 | 1.1% | |
Gross profit | Rs m | 4,103 | 415,389 | 1.0% | |
Depreciation | Rs m | 1,091 | 122,608 | 0.9% | |
Interest | Rs m | 944 | 29,793 | 3.2% | |
Profit before tax | Rs m | 2,334 | 262,988 | 0.9% | |
Minority Interest | Rs m | 0 | 1,195 | 0.0% | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -172,637 | 0.0% | |
Tax | Rs m | 624 | -3,211 | -19.4% | |
Profit after tax | Rs m | 1,711 | 94,756 | 1.8% | |
Gross profit margin | % | 25.7 | 27.4 | 93.9% | |
Effective tax rate | % | 26.7 | -1.2 | -2,188.8% | |
Net profit margin | % | 10.7 | 6.2 | 171.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 1,024,472 | 1.1% | |
Current liabilities | Rs m | 9,517 | 893,427 | 1.1% | |
Net working cap to sales | % | 9.4 | 8.6 | 108.8% | |
Current ratio | x | 1.2 | 1.1 | 101.0% | |
Inventory Days | Days | 110 | 91 | 121.7% | |
Debtors Days | Days | 35 | 96 | 36.3% | |
Net fixed assets | Rs m | 16,304 | 495,435 | 3.3% | |
Share capital | Rs m | 161 | 3,734 | 4.3% | |
Net worth | Rs m | 14,516 | 1,684,929 | 0.9% | |
Long term debt | Rs m | 4,189 | 775,597 | 0.5% | |
Total assets | Rs m | 29,805 | 3,466,480 | 0.9% | |
Interest coverage | x | 3.5 | 9.8 | 35.3% | |
Debt to equity ratio | x | 0.3 | 0.5 | 62.7% | |
Sales to assets ratio | x | 0.5 | 0.4 | 122.4% | |
Return on assets | % | 8.9 | 3.6 | 248.0% | |
Return on equity | % | 11.8 | 5.6 | 209.6% | |
Return on capital | % | 17.5 | 4.9 | 355.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 241,707 | 1.2% | |
From Investments | Rs m | -1,529 | -85,646 | 1.8% | |
From Financial Activity | Rs m | -941 | -289,944 | 0.3% | |
Net Cashflow | Rs m | 316 | -133,883 | -0.2% |
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare DISHMAN PHARMA With: FULFORD INDIA BIOCON WYETH ELDER PHARMA JUBILANT PHARMOVA
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
In this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More